Ignite Creation Date:
2025-12-25 @ 4:13 AM
Ignite Modification Date:
2026-02-24 @ 4:06 PM
Study NCT ID:
NCT03969420
Status:
TERMINATED
Last Update Posted:
2023-11-09
First Post:
2019-05-29
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
Sponsor:
Sumitomo Pharma America, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-01-15
Start Date Type:
ACTUAL
Primary Completion Date:
2021-04-22
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-05-14
Completion Date Type:
ACTUAL
First Submit Date:
2019-05-29
First Submit QC Date:
None
Study First Post Date:
2019-05-31
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2022-06-09
Results First Submit QC Date:
None
Results First Post Date:
2022-10-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-07
Last Update Post Date:
2023-11-09
Last Update Post Date Type:
ACTUAL